1. Peripheral biomarkers' panel for severe COVID‐19 patients
- Author
-
D'Alessandro, M., Bergantini, L., Cameli, P., Curatola, G., Remediani, L., Sestini, P., Bargagli, E., Siena COVID Unit, Bennett, D., Bianchi, F., Perillo, F., Lanzarone, N., Montagnani, F., Perrone, A., Franchi, F., Scolletta, S., Mazzei, M. A., Volterrani, L., Valente, S., Zanelli, G., Migliorini, L., Rossetti, B., Fabbiani, M., Vagaggini, C., Capecchi, P. L., Cusi, M. G., Frediani, B., Cubattoli, L., Mastrocinque, E., Cameli, M., Nardi, M., Bova, G., Mezzasalma, F., Guerrini, S., Santoro, A., Antonelli, G., Giacomin, E., Gentilini, R., Sansoni, A., Corbisiero, R., Mencarelli, M., Pippi, F., Marri, D., Lanari, A., Masini, M., Stella, G., Paglicci, L., Cassol, C., Valenti, R., Caffarelli, C., Gonnelli, S., Lapi, A., Gallo, S., Donati, G., Ceccarelli, E., Mattaliano, C., Sellerio, I., Conticini, E., Cantarini, L., and Marinetti, A.
- Subjects
Male ,Oncology ,medicine.medical_specialty ,COVID19 ,Lymphocyte ,T cell ,Cell ,macromolecular substances ,KL-6 ,Lymphocytes ,biomarker ,prognosis ,Severity of Illness Index ,03 medical and health sciences ,0302 clinical medicine ,Virology ,Internal medicine ,Severity of illness ,medicine ,Humans ,Lymphocyte Count ,030212 general & internal medicine ,Letter to the Editor ,Aged ,Retrospective Studies ,Innate immune system ,business.industry ,Mucin-1 ,COVID-19 ,KL‐6 ,Retrospective cohort study ,Middle Aged ,Lymphocyte Subsets ,Killer Cells, Natural ,Infectious Diseases ,medicine.anatomical_structure ,Biomarker (medicine) ,Female ,030211 gastroenterology & hepatology ,business ,Biomarkers ,CD8 - Abstract
It is widely reported in the literature that CD4, CD8 and total T cell count are significantly reduced in critically ill patients with COVID‐19. Few weeks ago, we suggested natural killer (NK) cell count as a marker of severity in 34 hospitalized COVID‐19 patients. On this topic, our research group firstly described a novel potential COVID19 severity marker, Krebs von den Lungen‐6. This study aimed to investigate how a combination of COVID19 severity markers could be helpful in the clinical management of these patients. The combination of these validated, reproducible and non‐expensive bioindicators showed a good accuracy in discriminating between severe and non‐severe patients, suggesting a promising value of this approach in the early prediction of a more aggressive disease phenotype. Despite its monocentric design, our study confirms the reliable dysregulation of innate immune responses, particularly involving NK cells, and suggests that surveillance of a peripheral biomarkers’ panel, including lymphocyte cell counts and KL‐6, may be useful in the clinical management of severe COVID‐19 patients. This article is protected by copyright. All rights reserved.
- Published
- 2020